Conflicts of Interest and Clinical Recommendations: Comparison of Two Concurrent Clinical Practice Guidelines for Primary Immune Thrombocytopenia Developed by Different Methods

American Journal of Medical Quality

Volumn 29, Issue 1, 2014, Pages 53-60

  George, James N ^a   Vesely, Sara K ^a   Woolf, Steven H ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

conflicts of interest; evidence evaluation; immune thrombocytopenia; practice guidelines

Indexed keywords

ALLOANTIBODY; RHO(D) ANTIBODY; THROMBOPOIETIN RECEPTOR;

ADULT; AGONISTS; CHILD; COMPARATIVE STUDY; CONFLICT OF INTEREST; CONSENSUS DEVELOPMENT; ETHICS; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; HUMAN; PRACTICE GUIDELINE; PROCEDURES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SPLENECTOMY; STANDARDS;

ADULT; CHILD; CONFLICT OF INTEREST; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; EVIDENCE-BASED MEDICINE; FINANCIAL SUPPORT; HUMANS; ISOANTIBODIES; PRACTICE GUIDELINES AS TOPIC; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, THROMBOPOIETIN; SPLENECTOMY;

EID: 84898910873     PISSN: 10628606     EISSN: 1555824X     Source Type: Journal    
DOI: 10.1177/1062860613481618     Document Type: Article

References (35)

1. None of the authors had any role in the planning, development, or external reviews of the clinical practice guidelines that are the subject of this report.
2. The authors declared the following potential conflicts of interest with respect to the research, authorship>and/or publication of this article: Dr George was chair of the guideline panel that produced the previous American Society of Hematology (ASH) clinical practice guideline for primary immune thrombocytopenia (ITP) published in 1996; he has served in leadership positions for ASH including president in 2005; he currently receives honoraria as a consultant for Amgen, Inc, and also receives research funding from Amgen, Inc, for clinical studies of romiplostim. Dr Vesely serves on the faculty for the ASH Clinical Research Training Institute; she served as a biostatistician on the Data Safety Monitoring Board of the APOLLO Study for Sanofi Pharmaceuticals 2002 to 2004. Dr Woolf was a methodology consultant for ASH from 1994 to 2000 and was a member of the 1996 ASH clinical practice guideline panel. He recently coauthored a background paper on guideline development that was commissioned by the Institute of Medicine and is cited in this article. He has never received financial support from the pharmaceutical industry.
3. The authors received no financial support for the research, authorship, and/or publication of this article.
4. Daly J. Evidence-Based Medicine and the Search for a Science of Clinical Care. Berkeley, CA: University of California Press; 2005.
5. Shaneyfelt TM Mayo-Smith MF Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA. 1999; 281: 1900-1905.
6. Grilli R Magrini N Penna A Mrua G Liberati A. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet. 2000; 355: 103-106.
7. Shaneyfelt TM Centor RM. Reassessment of clinical practice guidelines: go gently into that good night. JAMA. 2009; 301: 868-869.
8. Jones DJ Barkun AN Lu Y, et al. Conflicts of interest ethics: silencing expertise in the development of international clinical practice guidelines. Ann Intern Med. 2012; 156: 809-816.
9. Oxman AD Guyatt GH. The science of reviewing research. Ann N Y Acad Sci. 1993; 703: 125-133.
10. Guyett GH Cook DJ Jaeschke R Pauker SG Schunemann HJ. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 123S-131S.
11. Institute of Medicine. Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: National Academies Press; 2011.
12. Guyatt GH Akl EA Hirsh J, et al. The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med. 2010; 152: 738-741.
13. Choudhry NK Stelfox HT Detwiler TC. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002; 287: 612-617.
14. Rothman DJ McDonald WJ Berkowitz CD, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009; 301: 1367-1372.
15. Institute of Medicine. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press; 2011.
16. Brawley O Byers T Chen A, et al. New American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA. 2011; 306: 2495-2499.
17. Laine C Taichman DB Mulrow CD. Trustworthy clinical guidelines. Ann Intern Med. 2011; 154: 774-775.
18. George JN Woolf SH Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996; 88: 3-40.
19. British Committee for Standards in Haematology. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003; 120: 574-596.
20. Rodeghiero F Stasi R Gernsheimer T, et al. Standardization of terminology, definitions>and outcome criteria in immune thrombocytopenic purpura in adults and children: report from an international working group. Blood. 2009; 113: 2386-2393.
21. Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med. 2009; 60: 193-206.
22. Provan D Stasi R Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115: 168-186.
23. Neunert CE Lim W Crowther MA Cohen AR Solberg LA Jr Crowther M. The American Society of Hematology 2011 evidenced-based practice guideline for immune thrombocytopenia. Blood. 2011; 117: 4190-4207.
24. Agency for Healthcare Research and Quality. Definition of clinical practice guideline. http://www.guideline.gov/about/inclusion-criteria.aspx. Accessed July 15, 2012.
25. ApotheCom ScopeMedical. www.apothecomscopemedical.com. Accessed September 5, 2012.
26. Terrell DR Beebe LA Vesely SK Neas BR Segal JB George JN. Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol. 2012; 87: 848-852.
27. Kuter DJ Rummel M Boccia R, et al. Romiplostim or standard care in patients with immune thrombocytopenia. N Engl J Med. 2010; 363: 1889-1899.
28. Cochrane AL. Effectiveness and Efficiency: Random Reflections on Health Services. London, England: Nuffield Provincial Hospitals Trust; 1972.
29. Shekelle PG Woolf SH Eccles M Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999; 318: 593-596.
30. Institute of Medicine. Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: National Academies Press; 2009.
31. Hutchings A Raine RA. A systematic review of factors affecting the judgments produced by formal consensus development methods in healthcare. J Health Serv Res Policy. 2006; 11: 172-179.
32. Kahan JP Park RE Leape LL, et al. Variations by specialty in physician ratings of the appropriateness and necessity of indications for procedures. Med Care. 1996; 34: 512-523.
33. Murphy ER Dingwall D Greatbatch S Parker S Watson P. Qualitative research methods in health technology assessment: a review of the literature. Health Technol Assess. 1998; 2(16):iii-ix>1-274.
34. Fretheim A Schünemann HJ Oxman AD. Improving the use of research evidence in guideline development: 3. Group composition and consultation process. Health Res Policy Syst. 2006; 4: 15.
35. Eccles M Grimshaw J Shekelle PG Schünemann HJ Woolf SH. Developing clinical practice guidelines: target audiences, identifying topics for guidelines, guideline group composition and functioning and conflicts of interest. Implement Sci. 2012; 7: 60.